m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05500
 [1]
m6A modification MIR211 MIR211 METTL14 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-211 TCF12  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target microRNA 211 (MIR211)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator MicroRNA 211 (MIR211) microRNA View Details
Regulated Target Transcription factor 12 (TCF12) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary microRNA 211 (MIR211) is a novel tumor suppressor in T-cell lymphoblastic lymphoma,it regulated by METTL14. Targeting of miR-211/Transcription factor 12 (TCF12) axis is a potential treatment for T-cell lymphoblastic lymphoma patients.
Responsed Disease Lymphoma ICD-11: 2A70
 Disease Info 
Cell Process Cell viability
DNA synthesis
Spheroid formation
In-vitro Model
WA09
 N.A. Homo sapiens CVCL_9773
Jurkat T acute lymphoblastic leukemia Homo sapiens CVCL_0065
SUP-T1 Childhood T lymphoblastic lymphoma Homo sapiens CVCL_1714
CCRF-CEM T acute lymphoblastic leukemia Homo sapiens CVCL_0207
In-vivo Model Subcutaneously injected with 5 × 106 Jurkat cells and fed under Specific Pathogen Free (SPF) conditions. One week later, tumor mass was injected once a week with Agomir NC, Agomir-211, Antagomir NC and Antagomir 211, respectively, for three weeks.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2A70: Lymphoma 2 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Lisocabtagene maraleucel Approved [2]
Synonyms
JCAR017
    Click to Show/Hide
External Link
TTD: D0M4WU
 Compound Name MB-CART19.1 Phase 2 [3]
External Link
TTD: D0F1HT
References
Ref 1 MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF12. Leuk Res. 2021 Nov;110:106653. doi: 10.1016/j.leukres.2021.106653. Epub 2021 Jun 29.
Ref 2 ClinicalTrials.gov (NCT03743246) A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Ref 3 ClinicalTrials.gov (NCT03321123) MB-CART19.1 in Patients With R/R ALL